Roche Diagnostics S.P.A.
Monza, Lombardia Part of Foundation Medicine, Inc.
- UEI
- CRBLKCZC9XC6
- CAGE
- A2592
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Corporate family
-
-
Parent
Boston, MA
EHXPZ92G4AD1
-
Parent
Boston, MA
EHXPZ92G4AD1
- SAM.gov registration date
- Physical address
- Viale Gian Battista Stucchi, 110, 20900 Monza MB, Italy
- Website
- roche.com
- Founded
- 1896
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $45,817 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $45,817 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Clinical chemistry cost per reportable result | Defense Health Agency | $42,378 | |
| Clinical chemistry cost per reportable result | Defense Health Agency | $3,440 | |
| Lease of analyzer and usage of reagents | Medical Command (Army) | $98,062 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Sysmex Italia S.R.L. | Milano, Lombardia | 621511 Medical Laboratories |
| Humanitas Istituto Clinico Catanese S.P.A. | Sicilia | 622310 Specialty (except Psychiatric and Substance Abuse) Hospitals |
| Diatec - S.R.L. | Roma, Lazio | 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers |
| Astra Formedic S.R.L. | Milano, Lombardia | 621511 Medical Laboratories |
| Instrumentation Laboratory S.P.A. | Milano, Lombardia | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Roche Diagnostics S.P.A., a child entity of Boston-based Foundation Medicine, Inc., operates as a foreign-owned diagnostic testing and clinical chemistry services provider delivering in-vitro diagnostic substances and clinical chemistry analyzers to the Defense Health Agency as a prime contractor on a cost-per-reportable-result basis, with all work performed in Italy.
Roche Diagnostics S.P.A. is structured as a partnership or limited liability partnership headquartered in Monza, Italy. The vendor competes on a full-and-open basis with no set-aside designations. Its federal footprint is concentrated in clinical chemistry diagnostics under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing), delivering automated clinical chemistry analyzers, consumables, reagents, controls, and maintenance services to support blood testing at overseas military medical facilities.
The vendor's customer base is highly concentrated around two defense medical agencies. The Defense Health Agency accounts for three awards with a combined potential value of $876 thousand, while the Department of the Army Medical Command holds one award worth $130 thousand. Both rankings are identical — these two customers represent 100% of Roche Diagnostics S.P.A.'s recent federal award activity.
Roche Diagnostics S.P.A. holds a single-award indefinite-delivery contract (W9114F26DA005) with the Defense Health Agency, awarded January 1, 2026, with a $830 thousand ceiling and ultimate completion date of December 31, 2030. This IDIQ supports procurement and maintenance of an automated clinical chemistry analyzer performing 27 different blood chemistry tests with random access and STAT interrupt capability for the U.S. Army Health Clinic in Vicenza, Italy. The contract employs a cost-per-reportable-result pricing model with an estimated annual workload of 42,595 clinical chemistry tests. Two delivery orders have been issued under this IDIQ: a $3,439.76 firm fixed-price order issued January 2, 2026, completed February 28, 2026, and a $42,377.73 firm fixed-price order issued March 1, 2026, scheduled for completion September 30, 2026. One award carries an ultimate completion date within the next twenty-four months, representing a $42 thousand recompete exposure. Recent obligated spend stands at $144 thousand against a combined potential value of $1 million across all four awards in the source data.
Quick answers
Is Roche Diagnostics S.P.A. registered in SAM.gov?
Yes. Roche Diagnostics S.P.A.'s SAM.gov registration is active through September 28, 2027.
How much has Roche Diagnostics S.P.A. received in federal contracts?
Federal contracts obligated $45,817 to Roche Diagnostics S.P.A. in fiscal years 2023 through 2027.
What is Roche Diagnostics S.P.A.'s most recent federal award?
Roche Diagnostics S.P.A.'s most recent federal contract award is Clinical chemistry cost per reportable result (HT940626FE026), from Defense Health Agency, on March 1, 2026.
On GovTribe
See Roche Diagnostics S.P.A.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors